Altawalbeh Shoroq M, Almomani Basima A, Alefan Qais, Mohammad Momany Suleiman, Al-Share Qusai Y
Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Department of Internal Medicine, School of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Int J Pharm Pract. 2022 Nov 4;30(5):457-465. doi: 10.1093/ijpp/riac052.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Concerns have been raised about the influence of adverse drug effects on patient's health-related quality of life (HRQoL) in COPD patients. This study aimed to evaluate the impact of COPD treatment-related adverse effects on HRQoL in COPD patients.
In a cross-sectional study, COPD patients aged 40 years or older were identified and interviewed during their hospital visits. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaire was used for evaluating HRQoL. Potential treatment adverse effects were evaluated as experienced by participants during the last 2 weeks preceding the interview. The intensity of adverse effects was reported in the following categories: never, mild, moderate and severe. Multivariable linear regression model was performed to evaluate the influence of adverse drug effects on utility scores as an indicator of HRQoL.
A total of 203 patients diagnosed with COPD were recruited in the current study. The mean utility score of the study sample was 0.68 (SD = 0.36). Moderate-severe constipation, moderate-severe confusion, mild urinary hesitation, moderate-severe urinary hesitation, moderate-severe dry eyes and moderate-severe drowsiness were significant predictors/determinants for the average utility scores (coefficients were -0.099, -0.191, -0.111, -0.157 and -0.144, respectively). In addition, having higher COPD Assessment Test scores and severe disease was negatively associated with average utility scores (coefficients were -0.287 and -0.124, respectively).
Higher intensity of COPD treatment-related adverse effects has a negative influence on HRQoL in COPD patients. Anticholinergic drug effects are of concern in COPD adults' population.
慢性阻塞性肺疾病（COPD）是全球发病和死亡的主要原因。人们对药物不良反应对COPD患者健康相关生活质量（HRQoL）的影响表示担忧。本研究旨在评估COPD治疗相关不良反应对COPD患者HRQoL的影响。
在一项横断面研究中，识别出年龄在40岁及以上的COPD患者，并在他们就诊期间进行访谈。使用欧洲五维健康量表（EQ-5D-5L）问卷评估HRQoL。在访谈前的最后2周内，评估参与者经历的潜在治疗不良反应。不良反应的强度按以下类别报告：从未有过、轻度、中度和重度。采用多变量线性回归模型评估药物不良反应对作为HRQoL指标的效用得分的影响。
本研究共招募了203例诊断为COPD的患者。研究样本的平均效用得分为0.68（标准差=0.36）。中度至重度便秘、中度至重度意识模糊、轻度排尿犹豫、中度至重度排尿犹豫、中度至重度干眼和中度至重度嗜睡是平均效用得分的显著预测因素/决定因素（系数分别为-0.099、-0.191、-0.111、-0.157和-0.144）。此外，较高的COPD评估测试得分和严重疾病与平均效用得分呈负相关（系数分别为-0.287和-0.124）。
较高强度的COPD治疗相关不良反应对COPD患者的HRQoL有负面影响。抗胆碱能药物效应在COPD成年人群中值得关注。
